Join our cancer enterprise at Cedars-Sinai Cancer during a transformational period of growth and help us achieve our goal of becoming a top tier nationally recognized Cancer Center. We are seeking a senior melanoma research scientist to coordinate and direct basic and translational research of the Cutaneous Oncology Program. An endowed chair will be provided to the holder of this position.
Are you a scientist leader ready to drive the melanoma cancer research efforts of the Cedars-Sinai Cancer during an exciting period of growth? Join us and together we will develop a world class melanoma research program.
Are you right for this role? A successful candidate has a:
• proven track record of peer-reviewed cancer relevant extramural funding,
• extensive publication record in high impact peer-reviewed journals,
• successful track record of developing innovative research programs, and
• national or international prominence in melanoma cancer research
Interested candidates should send their CV, a cover letter as well as names of three references to Dr. Dan Theodorescu c/o AcademicRecruiting@cshs.org
Apply now! Academic.Recruiting@cshs.org
Cedars-Sinai seeks to find, develop and retain the best clinical and research faculty. We promote excellence through diversity and encourage all qualified applicants to apply. We are an equal opportunity/affirmative action employer, M/F/Vets/Disabled
The Cutaneous Oncology Program at Cedars-Sinai Cancer is internationally recognized with expertise in drug development, patient care, and translational research. Its focus lies in the field of immunotherapy including checkpoint inhibitors, bispecific antibodies, and adoptive cell therapy. Led by Drs. Mark Faries and Omid Hamid, the program has been instrumental to the development and FDA approval of checkpoint inhibitors over the last decade (nivolumab, ipilimumab, durvalumab, pembrolizumab, avelumab, atezolizumab) with a greater focus on next generation checkpoint targets, bispecifics, cell therapy, CAR-T cell and other cellular therapy products.
We are searching for an accomplished, federally funded research scientist with a demonstrated successful research program in melanoma. The Senior Research Melanoma Scientist in the Cutaneous Oncology Program will develop a comprehensive translational research (bench to bedside) program to study the pathophysiology, prevention, detection and treatment of primary and metastatic melanomas. The candidate will work collaboratively with cancer physicians and investigators across the Cedars-Sinai Health System in the development of a first- rate research, clinical and educational programs in melanoma. The scientist will work closely with the medical directors of the Cutaneous Oncology Program to develop groundbreaking discoveries to guide patient selection and therapies in the field of cancer immunology including the development of blood and tissue-based biomarkers. The scientist would leverage an established high-volume internationally recognized multidisciplinary oncology program with established clinically annotated biobank protocols in melanoma to develop new knowledge and apply that knowledge to novel paradigm shifting diagnostic, prognostic, predictive and therapeutic clinical protocols.
In this role, you will:
• Engage in peer-reviewed funded research in melanoma, either basic, translational, population, health services areas and/or clinical trials.
• Develop a comprehensive translational research program to study the pathophysiology, prevention, detection and treatment of primary and metastatic melanomas.
• Create a scientific culture and environment that promote the submission of research grants by Cutaneous Oncology Program members.
• Work to increase research funding from external sponsors and promote success of Cutaneous Oncology Program members in obtaining extramural peer-reviewed support from NIH, foundations and other agencies for research as well as from industry.
• Work collaboratively with cancer physicians and investigators across the Cedars-Sinai Health System in the development of research, clinical and educational programs in melanoma.
• Identify, mentor, and guide members of the Cutaneous Oncology Program.
• Promote the mentoring of young investigators in melanoma research.
• Advise and foster participation by interested and qualified attending staff physicians and trainees in relevant research areas.
• Participate with the Cedars-Sinai Cancer director in securing philanthropic support for the program.
• Develop and/or contribute to the development of training programs in melanoma related sciences with institutional educational leaders.
• Contribute to the training of clinical and research fellows and laboratory staff in translational, population, and basic research in melanoma.
• If so qualified, provide professional clinical and consultative expertise in melanoma therapy.
• MD, PhD or MD/PhD or equivalent from an accredited school and 5 or more years’ experience in melanoma research (basic, translational, prevention or clinical)
• For MD or MD/PhD, Board Certification in Internal Medicine, Surgery, Hematology/Oncology, Radiation Oncology or Pathology by the corresponding American Board or the equivalent.
• For MD or MD/PhD or equivalent, ability to obtain an unrestricted California medical license as Physician.
• Demonstrated record of leadership in developing cancer research programs
• Demonstrated excellence in melanoma research with outstanding peer-reviewed publications and proven abilities as Principal Investigator and mentor
• Excellent interpersonal, organizational, communication and mentorship skills
About Cedars-Sinai Cancer
Ranked by US News & World Report as the #7 Best Hospital in Cancer Nationally and #1 in California in 2020-2021, the Cedars-Sinai Cancer program sees over 4800 new cases of cancer per year and is part of the Cedars-Sinai Health System, a rapidly expanding vertically integrated health system with practices located in Southern California, including Tower Hematology- Oncology, The Angeles Clinic and Research
Institute, Cedars-Sinai Valley Oncology Medical Group, Cedars-Sinai Marina del Rey hospital, Hunt Cancer Institute at Torrance Memorial, and Cedars-Sinai Medical Center.
Cedars-Sinai Cancer continues to pursue excellence with plans to greatly expand and sharpen the focus of its basic and translational research programs and its studies of populations and cancer disparities that are unique to its geographic area, focusing on cancer prevention and helping to change behaviors to ensure a healthier lifestyle.
Along with caring for patients, Cedars-Sinai is a hub for biomedical research and a top 10 academic medical center for NIH funding with over $200M in extramural research grant funding. As the largest academic medical center in the western United States, Cedars-Sinai is also training the next generation of physicians, researchers, and allied health professionals. Physicians and scientists at Cedars-Sinai are actively engaged in translational research to bring medical advancements directly from the laboratory to the bedside.
A commitment to meeting the community's health needs has been a defining quality of Cedars-Sinai since the beginning - from the opening of the 12-bed Kaspare Cohn Hospital in Angeleno Heights in 1902 to what is now a world-renowned, nonprofit academic medical center with 890 licensed beds.
Ranked by US News & World Report as the #7 Best Hospital in 2020-2021, Cedars-Sinai is a leader in providing high-quality healthcare encompassing primary care, specialized medicine and research. Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the nation, setting standards in quality and innovative patient care, research, teaching and community service. Today, Cedars- Sinai is known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare by developing new approaches to treatment and educating tomorrow's health professionals. Additionally, Cedars-Sinai demonstrates a commitment to the community through programs that improve the health of its most vulnerable residents.